Michelle Molina
Neurology · Ramsey, NJNPI 1235530007
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 90.1% of the total across 89 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 22 manufacturers, the largest accounting for just 22.4% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $792 and has fallen 66.8% since, to $263 in 2025. That places this record below the midpoint for neurology clinicians in NJ, where the typical reported total is $1,560.
Across 89 payments — averaging $19.93 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$397
- Acorda Therapeutics, Inc$176
- Biogen$159
- UCB, Inc.$146
- Lilly USA, LLC$119
- GE HealthCare$105
- plus $672 from 16 others
What the payments were for
- Speaking & faculty fees$17610%
- Food & beverage$1,59890%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 19 | $397 |
| Acorda Therapeutics, Inc | 10 | $176 |
| Biogen | 8 | $159 |
| UCB, Inc. | 8 | $146 |
| Lilly USA, LLC | 7 | $119 |
| GE HealthCare | 5 | $105 |
| AstraZeneca | 2 | $86 |
| Sanofi | 4 | $83 |
| Teva Pharmaceuticals USA, Inc. | 4 | $76 |
| Novartis | 4 | $72 |
| Lundbeck LLC | 2 | $47 |
| Kyowa Kirin, Inc. | 2 | $42 |
| OPKO Pharmaceuticals, LLC | 2 | $37 |
| Merck | 2 | $34 |
| Neurocrine Biosciences, Inc. | 2 | $33 |
| Pfizer | 2 | $28 |
| Grifols USA, LLC | 1 | $27 |
| Novo Nordisk | 1 | $25 |
| Neurelis, Inc. | 1 | $23 |
| Amneal Pharmaceuticals LLC | 1 | $21 |
| Vifor Pharma, Inc. | 1 | $19 |
| Acadia Pharmaceuticals Inc | 1 | $18 |
How this compares
$1,774 in reported general payments places this provider in the 50th percentile of 521 neurology providers in New Jersey.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| InbrijaLevodopa | 13 | $32,223 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Acorda Therapeutics, IncInbrija | $176 | $32,22313 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 521 neurology providers in New Jersey.
Other neurology in Ramsey
- Steven BromleyAudubon$1.5M
- Mary Ann PiconeTeaneck$1.5M
- Fiona GuptaOradell$1.1M
- Matthew DavisMiddletown$567K
- Amos KatzEatontown$558K
- Monte PellmarFreehold$429K
- Marcie RabinSummit$387K
- Ashish KapoorBayonne$329K
- Mario VukicHackensack$310K
- Andrew SylvesterBridgewater$296K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.